The pharmacotherapy of heparin-induced thrombocytopenia (HIT): A review of contemporary therapeutic challenges in clinical practice
- Author:
Yahaya Hassan
;
Ahmed Awaisu
;
Ahmad AbdulRahman Al-Meman
;
Noorizan Abd. Aziz
- Publication Type:Review
- Keywords:
heparin-induced thrombocytopenia, HIT, therapeutics, fondaparinux, bivalirudin, drotrecogin-alfa (activated), lepirudin, argatroban, danaparoid
- From:Malaysian Journal of Medical Sciences
2008;15(2):3-13
- CountryMalaysia
- Language:English
-
Abstract:
Our objectives were to discuss a general overview on the description and recognition of heparin–induced thrombocytopenia (HIT) and present a critical review of the
traditional and most recent advances in its pharmacotherapy. Computerized searches were done on MEDLINE and Iowa Drug Information Service (IDIS)
databases from June 2001 until June 2007 and from May 2005 until May 2007, respectively. Search terms used included ‘heparin-induced thrombocytopenia’,
‘heparin-associated thrombocytopenia’, therapeutics, HIT, HAT. We largely selected publications within the timeframe above, but did not exclude commonly
referenced and highly regarded older publications. The commonly referenced published articles were obtained through manual searches derived from
bibliographic citations and retrievals from the authors’ personal files. Pertinent literatures (89 key articles) that were thought to have substantially contributed
new information to the therapeutics of HIT within the last 6 years were identified, reviewed and presented. The following limits were used for the MEDLINE and
IDIS searches: ‘human’, drug therapy’, ‘review’, ‘meta-analysis’, ‘clinical trial’, and case reports. The therapeutics of HIT is rapidly evolving and needs to consider an evidence – based approach. It is imperative that practitioners be aware of the
associated risk and be up-to-date with the current advances in the management of this fatal clinical condition.
- Full text:W020151019322883412331.pdf
